Liver Cirrhosis Treatment Market is Analytically Growing at a Promising CAGR of 5.2% During Forecast 2019-2025


Market Highlights:
Liver cirrhosis is basically the late-stage scarring of the liver caused due to various types of liver diseases and disorders such as alcoholism and hepatitis, among others. No symptoms are observed until the liver is extensively damaged. Complications of liver cirrhosis include portal hypertension, leg & abdomen swelling, splenomegaly, bleeding, infections, malnutrition, hepatic encephalopathy, jaundice, bone diseases, risk of liver cancer, and multi-organ failure.
According to MRFR analysis, the global Liver Cirrhosis Treatment Market is expected to register a CAGR of 5.2% during the forecast period of 2019 to 2025 and was valued at USD 956.89 million in 2018.
The growth of the global liver cirrhosis treatment market is driven by various factors such as an increasing global geriatric population, rising prevalence of liver cirrhosis, rapidly changing lifestyle, growing awareness programs regarding liver diseases, rising R&D investment for the development of innovative drugs for liver diseases, and increasing demand for better treatment methods for curing liver cirrhosis. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for liver cirrhosis are the factors that are expected to limit the growth of the global liver cirrhosis treatment market.
The global liver cirrhosis treatment market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
Key Players:
Some of the key players in the global liver cirrhosis treatment market are Pfizer, Inc. (US), Merck & Co., Inc. (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Gilead Sciences, Inc. (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), Shionogi Inc. (Japan), and Promethera (Belgium)
Segmentation:
·         The global liver cirrhosis treatment market has been segmented based on treatment, and end user.
·         The global liver cirrhosis treatment market has been segmented, on the basis of treatment, into antibiotics, immunosuppressants, and others. The antibiotics segment is expected to hold the majority share of the market as antibiotics are the most preferred type of prescribed drugs for liver cirrhosis patients due to high risk of infections.
·         The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others.
Regional Analysis:
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of liver cirrhosis and high geriatric population. The liver cirrhosis treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European liver cirrhosis treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The liver cirrhosis treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of liver cirrhosis and raising awareness about the disease, the market in Asia-Pacific is expected to be the fastest-growing. The liver cirrhosis treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Comments

Post a Comment

Popular posts from this blog

Proteomics Market Analysis, Demand Overview, Growth Analysis, Current Trends, Updates, and Global Industry Forecast to 2023

Market Highlights: The global proteomics market is anticipated to hold a market value of USD 23.2 billion in the year 2017 and is expected to grow at a CAGR of 14.1% during the forecast period. Proteomics is a science which is used to estimate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. Also, it has extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis. Increasing need for personalized medicine, R&D expenditure, technological advancements and increased funding for proteomics project are expected to drive the market growth over the forecast period. For instance, in July 2017, Biognosys AG received USD 5 million funding from its new as well as existing investors. These new funds will be used for extending commercial operations and also to accelerate the development of next generation prote...
Read more

Pancreatic Cancer Market: America to Command the Largest Share

Market Overview: Pancreatic cancer can be defined as an enlarged tumor, which is generally caused by malignant cells present in the tissues of the pancreas. This type of cancer is generally caused due to drinking alcohol, smoking, genetic factors, radiotherapy in the past, obesity, inflammation of the pancreas, and diabetes mellitus. It is a type of cancer that starts in the pancreas and is a highly lethal disease. The global Pancreatic Cancer Market , as per a report by Market Research Future (MRFR) is touted to register 8.1% CAGR during the forecast period ( 2017-2023 ). The dearth of therapeutic approaches for early-stage detection has resulted in increased incidences of pancreatic cancer. Soaring prevalence of pancreatic cancer has resulted in germline mutations, thereby causing the defective genes to pass down to the children from their parents, thus making early detection of pancreatic cancer important. This has led to the growth of the market across the globe. Surging dem...
Read more

Immune Thrombocytopenia (ITP) Market is Estimated to Record Promising CAGR of 5.78% During Forecast 2018-2023

Market Highlights: As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers. ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ...
Read more